Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumour necrosis factor therapy

Clinical and Experimental Rheumatology

Volumn 31, Issue 1, 2013, Pages 118-121

  Lee, Young Ho ^a   Bae, Sang Cheol ^b   Song, Gwan Gyu ^a  

^a Korea University College of Medicine   (South Korea)

^b Hanyang University Medical Center   (South Korea)

Author keywords

Anti tumour necrosis factor therapy; Hepatitis B virus occult carrier; Hepatitis B virus reactivation

Indexed keywords

ADALIMUMAB; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIGEN; INFLIXIMAB; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS DNA;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; VIRUS REACTIVATION;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; RHEUMATIC DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84874818081     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. DESAI SB, FURST DE Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-90.
2. NATHAN DM, ANGUS PW, GIBSON PR Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366-71.
3. GANEM D, PRINCE AM Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
4. DOMM S, CINATL J, MROWIETZ U The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-28.
5. PEREZ-ALVAREZ R, DIAZ-LAGARES C, GARCIA-HERNANDEZ F et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-71.
6. LAN JL, CHEN YM, HSIEH TY et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011; 70: 1719-25.
7. MORI S Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-7.
8. URATA Y, UESATO R, TANAKA D et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23.
9. TAMORI A, KOIKE T, GOTO H et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAgnegative cohorts. J Gastroenterol 2011; 46: 556-64.
10. CASSANO N, MASTRANDREA V, PRINCIPI M et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-9.
11. VASSILOPOULOS D, APOSTOLOPOULOU A, HADZIYANNIS E et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-5.
12. KIM YJ, BAE SC, SUNG YK et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-50.
13. CAPORALI R, BOBBIO-PALLAVICINI F, ATZENI F et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/ anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-54.
14. CHARPIN C, GUIS S, COLSON P et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179.
15. MADONIA S, ORLANDO A, SCIMECA D, OLIVO M, ROSSI F, COTTONE M Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508-9.
16. MATSUMOTO T, MARUSAWA H, DOGAKI M, SUGINOSHITA Y, INOKUMA T Adalimumabinduced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 2010; 30: 1241-2.
17. LORAS C, GISBERT JP, MINGUEZ M et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-6.
18. CHEN DS Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19-25.
19. KAO JH Molecular epidemiology of hepatitis B virus. Korean J Intern Med 2011; 26: 255-61.
20. SCHLAAK JF, TULLY G, LOHR HF, GERKEN G, MEYER ZUM BUSCHENFELDE KH HBVspecific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999; 115: 508-14.
21. ROQUE-AFONSO AM, FERAY C, SAMUEL D et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 95-9.